Bristol-Myers Squibb to Unveil New Data

Bristol-Myers Squibb said pre-market Wednesday that it will present research related to the treatment of rheumatoid arthritis patients with highly active, progressive disease, including new data on the role of biomarkers and MRI in RA patient identification and treatment. The research, which includes analyses relating to Orencia treatment responses in patients with high active, progressive RA who traditionally have a poor prognosis, will be presented at the annual European Congress of Rheumatology in Madrid, Spain. The drug maker also said it will unveil first-in-human data on investigational TYK2 inhibitor BMS-986165.

The research “shows our commitment to advancing scientific understanding of how biomarkers and tools, such as MRI, can be used to guide patient selection and treatment in highly active, progressive rheumatoid arthritis,” said Brian Gavin, vice president of Orencia development lead at Bristol-Myers Squibb.

By Chris Robinson